N2OFF's MitoCareX Bio Sees Progress in Precision Oncology Market.
ByAinvest
Tuesday, Nov 18, 2025 9:15 am ET1min read
NITO--
N2OFF, a cleantech company, has acquired MitoCareX Bio Ltd. and shared an update from CEO Dr. Alon Silberman. MitoCareX is a biotechnology company that uses its proprietary algorithm, MITOLINE, to develop novel therapies for hard-to-treat cancers through drug discovery. The company plans to focus on precision oncology and has outlined its strategic direction, near-term milestones, and development plans.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet